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a b s t r a c t
Purpose: To promote consistency in clinical trials by recommending a uniform framework as it relates to
radiation transport and dose calculation in water versus in medium.
Methods: The Global Quality Assurance of Radiation Therapy Clinical Trials Harmonisation Group (GHG;
www.rtqaharmonization.org) compared the differences between dose to water in water (Dw,w), dose to
water in medium (Dw,m), and dose to medium in medium (Dm,m). This was done based on a review of historical frameworks, existing literature and standards, clinical issues in the context of clinical trials, and
the trajectory of radiation dose calculations. Based on these factors, recommendations were developed.
Results: No framework was found to be ideal or perfect given the history, complexity, and current status
of radiation therapy. Nevertheless, based on the evidence available, the GHG established a recommendation preferring dose to medium in medium (Dm,m).
Conclusions: Dose to medium in medium (Dm,m) is the preferred dose calculation and reporting framework. If an institution’s planning system can only calculate dose to water in water (Dw,w), this is
acceptable.
Ó 2021 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 159 (2021) 106–111 This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

To maximize the power of clinical trials, and to ensure results
are broadly interpretable, it is essential that dose be calculated
consistently across all participating institutions [1]. Clinical practice must also be consistent with the framework of clinical trials
to ensure that patients maximally benefit from the results of trials.
As current trials are often international, these issues need global
consideration and endorsement. Therefore, the Global Quality
Assurance of Radiation Therapy Clinical Trials Harmonisation
Group (GHG; https://rtqaharmonization.org/) promotes uniform
standards for clinical trials involving radiation therapy [2].
⇑ Corresponding author at: 8060 El Rio, Houston, TX 77054, USA.
E-mail address: sfkry@mdanderson.org (S.F. Kry).

One inconsistency in radiation oncology is the medium in
which radiation transport and dose deposition are calculated.
While radiotherapy equipment is calibrated in terms of dose-towater according to protocols such as TRS-398 [3], TG-51 [4,5], or
the UK protocol [6,7], the corresponding dose calculation in the
treatment planning system (TPS) is not consistent in terms of
which medium is used and can be described either as dose to water
or dose to medium.
The medium of radiation transport and dose deposition is only
one difference between different algorithms that affects dose calculation accuracy. Different algorithms have different inherent
accuracies [8–13], particularly at interfaces [14–17]. Nevertheless,
the medium of transport and calculation remains substantially

https://doi.org/10.1016/j.radonc.2021.03.006
0167-8140/Ó 2021 The Authors. Published by Elsevier B.V.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Radiotherapy and Oncology 159 (2021) 106–111

S.F. Kry, J. Lye, C.H. Clark et al.

inconsistent across radiation oncology practice [18]. This topic is
an issue of ongoing debate [19], and represents an opportunity
for a more uniform solution. This report therefore focuses on this
single issue of how to achieve the most consistency in terms of
the medium of radiation transport and dose calculation.
This issue is most studied for megavoltage external photon
beams and this report therefore focuses on this application. However, identical questions exist in relation to brachytherapy, particle
beam therapy, or kV applications. Particularly as external beam
therapy is often coupled with, or directly compared to, brachytherapy or particle beam therapies, the need for consistency in dose
reporting between treatment modalities is clear.

Dosimetric differences
These three different approaches to dose calculation yield different doses in different media. It is worth noting that these differences do not arise because of differences in density: dose is energy
deposited per unit mass and when density increases, both deposited energy and mass increase proportionally. Rather, this issue is
about chemical composition and its impact on photon and electron
interaction cross sections. Biological tissues are chemically different from water, and as such, dose deposition is different in these
as compared to water.
Dose differences are illustrated in Fig. 2, which shows a percentage depth dose for a 6 MV photon beam with different slabs of
material calculated with dose to medium (Dm,m) and dose to water
(Dw,m and Dw,w). Some things are immediately apparent: (1) None
of the three options agree with each other, (2) the difference in
dose is most pronounced for bone, (3) the Dw,w algorithms show
smooth behaviour at interfaces instead of the build-up and builddown regions that really exist, and (4) as is particularly evident
in bone, Dw.m can be further away from conventional dose to water
(Dw,w) than the dose to medium (Dm,m) results. This last point is
particularly interesting as Dw,m was introduced mainly to reproduce historical Dw,w results [20], which, in fact, it does not do
[19,21,22].

Dose specification in radiotherapy
The medium for radiation transport and dose calculation is handled differently in different treatment planning systems. There are
actually three separate quantities used to specify the dose:
1. Dose to medium, as implemented in some Superposition/Convolution (S/C) algorithms (including Monaco, Oncentra, and
Pinnacle), the Grid Based Boltzmann Solver (GBBS; Acuros
AXB), and most Monte Carlo (MC) algorithms (including Cyberknife, iPlan, Monaco, and Raysearch): dose to medium-inmedium, Dm,m.
2. Dose to water with variable electron density, as implemented in
some S/C (including Xio, Raysearch, and Tomotherapy), as well
as in the Anisotropic Analytical Algorithm (AAA), Pencil Beam
(PB) algorithms, and one Monte Carlo implementation (ViewRay): dose to water-in-water, Dw,w.
3. Dose to water converted from dose to medium using post processing. This is implemented commonly with stopping power
ratios (as in some MC) as the dose to a small Bragg-Gray cavity
of water surrounded by the medium: dose to water-in-medium,
Dw,m [20].

1) Soft tissue
In soft tissue, the difference between Dm,m and Dw,w is systematic and relatively uniform in slab geometries: Dm,m is lower than
Dw,w by 0.7% to 1.4% in megavoltage beams across a range of beam
energies, depths, and different compositions of soft tissue and
muscle [18]. Evaluations of clinical treatment plans found similar
results, with an average difference in mean dose of 1.0–1.4%
between Dm,m and either Dw,w or Dw,m [23,24]. Dw,m and Dw,w were
found to agree within 0.1% [24].
2) Lung

These three different approaches are shown in Fig. 1. A review
of how major commercial algorithms handle radiation transport
and dose deposition is available in the AAPM TG-329 report [18].

In lung, differences between Dm,m, Dw,m, and Dw,w have been
noted. In clinical lung plans, the D100 (i.e., the minimum target

Fig. 1. Illustration of the different conceptual approaches used to calculate dose in a voxelized geometry for (a) a TPS calculating dose to variable density water (Dw,w), (b) a
TPS calculating dose to the medium of each voxel (Dm,m), and (c) the conversion back to dose to water from the dose to medium using stopping power ratios (Dw,m).
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Fig. 2. The depth dose curves through slabs of different media with a 6 MV beam calculated with (a) Eclipse AcurosXB dose to water (Dw,m) and dose to medium (Dm,m) and
AAA (Dw,w), (b) Monaco MC dose to medium (Dm,m) and dose to water (Dw,m) and Xio (Dw,w).

actually delivered to the bone when Dm,m is used, and the lowest
dose is delivered to the bone when Dw,m is used. A higher dose is
likely to improve control of bone disease receiving curative intent
[32] but could also increase the risk of side effects when bone is an
organ at risk.
In addition to being the largest effect, bone is also a conceptually interesting case because it has a complex physical structure
with varying densities of bone as well as marrow. A recent detailed
Monte Carlo investigation found similar results between Dw,m and
Dm,m for thoracic spine. For the cranium, Dw,m was closest calculation of the actual bone marrow dose, suggesting a preference for
Dw,m [33]. However, other studies have reasoned that, based on
current CT and TPS voxel resolution, the average voxel dose is best
described by Dm,m [22].

dose) was lower by 5% on average and target coverage was
incomplete when plans originally calculated with AAA (Dw,w) were
re-calculated with Acuros dose to medium (Dm,m); Acuros dose to
water (Dw,m) and AAA (Dw,w) were statistically equivalent [25].
However, smaller effects were reported when less sensitive metrics were evaluated, such as D98 [26].
3) Bone
The most pronounced differences are seen in bone (as seen in
Fig. 2), which can be relevant as a site of treatment or an organ
at risk. In slab geometries involving dense bone, Dm,m can be more
than 10% less than Dw,m, with Dw,w falling in between [21,22,27].
In clinical situations the effect is smaller. In head and neck
plans, the Dm,m (Acuros) average dose to bone was 2.4% lower than
with Dw,w (AAA), and 4.2% lower than with Dw,m (Acuros) [24]. Clinical spine plans showed a difference in mean dose of only 2.9% on
average (range: 1.7–4.2%) between Dm,m and Dw,m (Monte Carlo
iPlan) [28]. Clinical prostate plans showed a difference in mean
femoral head dose of 5.1% on average (range: 4.3–6.2%) between
Dm,m and Dw,m [23]. As a relatively extreme clinical example, the
cranium is part of the PTV for dermal sarcomas and the authors
of this report found differences of approximately 8% in volumetric
parameters depending on the dose specification. In general, the
reduced impact of medium specification in clinical situations (2–
8%) versus slab geometries (>10%) makes sense. Slab geometries
tend to be based on dense cortical bone, whereas actual bone is
typically less dense. This is accentuated in the clinic because many
bone diseases, including plasmacytomas and several common
metastases, are lytic (bone dissolving) [29], further reducing the
density of bone and its difference with soft tissue. However, there
are situations when the effect in a clinical situation may be more
pronounced. For example, bisphosphonates may be given to
patients to strengthen the bone [30] (which they do by increasing
the density of the bone at the site of metastases). These mechanically strengthen the bone, but by doing so they may act to increase
the dose (Dm,m) and act as a local radiation booster.
Using dose to bone in the TPS will predict a lower dose than
dose to water (either Dw,m or Dw,w) (as well as changing the fluence/dose optimization in intensity modulated radiotherapy
[31]). Therefore, for the same calculated dose, the highest dose is

Considerations for clinical trials
While not a dramatically large issue, the choice of medium is an
important question because it is a systematic issue that affects the
dose calculation and reporting for all patients. The recent IAEA
report on accuracy requirements emphasized that systematic dosimetric issues should be controlled at the 1–2% level [34]. This highlights that even the 1% difference between soft tissue and water is
an important distinction that should be made uniform. There are
reasons to prefer each of Dm,m and Dw,w, and even Dw,m. In this section we review the merits and rationale for considering each.
1) Clinical and clinical trial experience
Clinical experience and the history of clinical trials is varied. In
some regions (e.g., Europe, Australia) doses were intended as ‘‘to
water”, and dose response data and clinical experience are primarily based on dose to water. However, this is complicated because
the S/C algorithms of Pinnacle, Oncentra, and Monaco inherently
report Dm,m (or at least are best described by Dm,m, [18]), so many
of the dose-to-water data are, in fact, based on dose-to-medium.
In contrast, North American clinical trials have always been
defined as ‘‘dose-to-muscle” and dose response and clinical experience are based primarily on this framework. For algorithms that
inherently calculated dose to water, the linac calibration was typically modified by 0.99 to produce a dose-to-muscle calculation
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While the dose differences between Dm,m and Dw,w are relatively
small for megavoltage beams, this is not the case for energies in the
kV range. Here differences greater than 5% are usual in soft tissue,
and differences can exceed 100% in bone [37]. While kV is rarely
used for treatment in clinical trials, it remains a clinically utilized
modality, and it is a common energy for pre-clinical studies that
can define trial design. Additionally, kV imaging beams are regularly used in image guidance procedures for megavoltage treatments and can, in some situations, contribute nontrivial doses to
the treated volumes, including organs at risk [38]. Displaying the
sum of the doses from imaging and treatment beams is desirable
in the latter case and necessitates a consistent dose reference.
When kV energies are employed, a Dw,w approach should be
expected to produce a substantially different dose than a Dm,m
framework. This application further emphasizes the need to standardize on the most accurate solution.

[18]. However, this was never applied consistently, or necessarily
appropriately, as different algorithms inherently calculate dose differently [18]. In summary, it is hard to say that the global experience shows a preference for selection of Dm,m versus Dw,w,
although it does highlight the need for standardization. No trials
or clinical experience has been intentionally based on a Dw,m
framework, although almost certainly some small subsets of Dw,m
data have been present.
2) Clinical significance
The dose difference between Dm,m and Dw,w is ~1% in soft-tissue.
While this would not show an obvious clinical impact over a small
number of patients, it may be relevant for a large number of
patients, such as in a clinical trial [34] or indeed the broad clinical
practice of radiation oncology. The dose difference in soft tissue is
particularly relevant because the vast majority of clinical trials
involve tumours and organs at risk that have a soft tissue nature.
Therefore, there is considerable benefit to select a consistent, and
most accurate, calculation of dose in soft tissue.
Dose to bone typically differs by 2 to 5% between Dm,m and Dm,w,
with Dw,w falling inbetween. The magnitude of this difference is
larger than the 1% in tissue, and in a clinical trial setting with a
large number of patients it certainly represents a sizeable dose difference with the potential to perturb the outcome and add additional noise for bone-dependent outcomes. As discussed
previously, the complexity of bone raises questions about what
dose reporting framework makes most sense conceptually, and
arguments have been made for Dm,m [22] and Dw,m [33]. While a
Dw,m approach may be conceptually appealing for bone marrow
effects, other bone effects (e.g., fractures) may not be accurately
captured by this framework. Also problematic is that soft-tissue
would not be modelled as soft-tissue in such a framework, and
additionally there is an absence of clinical experience or outcome
data using Dw,m.

6) Measurement based validation of calculated doses
Measurements in water are the norm and standards are well
established through calibration protocols and inter-compared regularly (Key Comparison Database, https://www.bipm.org/kcdb/).
When water is the medium of interest, there is a direct link
between measurement and calculation based on Dw,w. However,
when the medium is not water (e.g., soft tissue or bone), direct
measurement and validation are not well defined. For soft tissue,
detectors have sometimes been calibrated in terms of dose-tomuscle by scaling the dose delivered to water by 0.99 [18]. While
this provides a reasonable estimate of dose to muscle, there is clear
room to improve this approach. There is less precedent for measurement of dose in bone, and effort is needed to improve the
capacity and standardization for direct measurement in bone.
One solution could be for the TPS to calculate Dm,m for patient
calculations, but also calculate Dw,w for validation measurements
in a water phantom. Ideally, and particularly for credentialing for
clinical trials, a more rigorous solution would employ quality
assurance using an anthropomorphic phantom with measurements in non-water materials such as soft tissue, bone and lung.
Such measurements are more complex but provide a closer
approximation to true patient dosimetry. These measurements will
require correction factors as detector calibrations currently relate
to dose to water. Conducting such measurements and determining
these factors first requires that a consistent approach to dose definition be established, which is the goal of this work.

3) Coordination with established guidelines
Historically, recommendations have been varied. In 2007 the
AAPM TG-105 report recommended that TPSs, when possible,
should be able to calculate both Dm,m and Dw,m [20]. In 2010 the
ICRU recommended a Dw,m framework [35]. However, as the substantial differences between Dw,m and Dw,w became more apparent,
more recent recommendations have shown a preference for the
use of dose to medium. Both the NRG and TROG have endorsed
reporting dose-to-medium for clinical trials (Dm,m) [36], which is
also consistent with the AAPM TG-329 framework on this topic
[18]. Given the increasingly international nature of clinical trials,
there is a clear advantage in having a broadly unified framework.

Recommendations
Based on the above considerations, the following recommendations are made with the goal of improving the consistency of dose
in clinical trial data and minimising uncertainty in the future.
These recommendations are made with the understanding that
no approach is 100% preferred over the others, but also that only
one framework should be endorsed overall.

4) Radiation transport
Most of the latest algorithms (Monte Carlo and GBBS) inherently transport radiation through the actual medium. This makes
sense as it is conceptually the most coherent approach and is
inherently the most accurate way to manage radiation transport.
It also means that Dm,m is directly calculated and available in the
most advanced and accurate algorithms available. In contrast, converting this value to dose to water (Dw,m) is not an accurate representation of dose to water, nor is it consistent with historical
‘‘dose-to-water” values [21,22]. The dose-to-water frameworks
(Dw,m or Dw,w) do not take advantage of the most accurate dose calculation frameworks available.

1. The Global Harmonization Group recommends calculating and
reporting dose in a Dm,m framework where possible.
2. Many algorithms do not allow the user to select the medium of
dose calculation. In such a case, the user should report whatever
is determined by the TPS, and Dw,w is acceptable.
3. The GHG does not recommend conversion from Dm,m to Dw,m.
4. For consistency, recommendations 1–3 should be broadly
applied across modalities and treatments, including external
beam therapy, but also in particle therapy, brachytherapy, and
pre-clinical studies.

5) kV conditions
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5. For the future, as vendors develop and refine their radiation
transport and dose calculation frameworks, a Dm,m framework
should be implemented to maximize consistency.
6. The dose calculation framework, particularly if changes are
made in clinical practice, should be documented and understood by all involved parties.
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Implications and conclusion
These recommendations have implications for clinical trials as
well as for clinical practice. Due to the inconsistent management
of this issue at present, transitioning to a common Dm,m framework
will necessitate changes in the specifications for many future clinical trials, as well as clinical practice for many institutions.
For clinical trials, the proposed framework will provide standardization of dose reporting for future trials, and consequently
will allow for clear interpretation of outcome data moving forward.
Historical trial data for soft tissues will be substantially equivalent,
and while historical trial data for bone may show differences, the
historical data is not cleanly defined in terms of Dw,w or Dm,m (as
described earlier) and therefore does not, at present, represent
any form of standard on this issue.
In terms of clinical practice, the oncologist’s clinical experience
should substantially translate smoothly as the changes discussed
here are small for the majority of clinical scenarios. The uncertainties from dose reporting, although not unimportant, are small compared to the biological uncertainties. The use of Dm,m versus Dw,m
for clinical nasopharyngeal or lung patients results in minimal
DVH differences in the target or organs at risk [39]. There is potential for clinically important differences for bony structures with
doses already close to the tolerance limit. Such cases may require
additional care. However, it should be noted that for most of the
advanced algorithms (Monte Carlo or Acuros), there is no available
calculation of Dw,w. A move away from an older Dw,w algorithm will
therefore produce a different result regardless of how the new
algorithm is implemented, and so clinical re-evaluation would
always be necessary. An interesting additional advantage of the
Dm,m framework presented here is that Dm,m is actually numerically
closer to Dw,w, and therefore represents a smaller change than to
Dw,m.
The inconsistency in the medium in which dose deposition is
calculated in radiation oncology can cause several percent of difference, particularly in tissues such as bone. Currently different TPSs
have taken different approaches and calculate in differing ways.
The Global Harmonization Group for QA in clinical trials proposes
a consensus that, where available, dose-to-medium should be
reported to maximize consistency.
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